Prenetics Announces Fourth Quarter and Full Year 2023 Financial Results
Prenetics Global Limited - Class A Ordinary Share (PRE)
Company Research
Source: GlobeNewswire
HONG KONG, April 01, 2024 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading genomics-driven health sciences company, today announced unaudited financial results for the fourth quarter and full year ended December 31, 2023, along with recent business updates. Financial Highlights Revenue from continuing operations of US$21.7 million in the full year 2023, an increase of 65.2% as compared to the full year 2022.Revenue from continuing operations of US$5.4 million in the fourth quarter 2023, an increase of 90.8% as compared to the fourth quarter 2022.Adjusted EBITDA from continuing operations of US$(24.8) million in the full year 2023.Adjusted EBITDA from continuing operations of US$(6.2) million in the fourth quarter 2023.Cash and other short-term assets1 of US$93.7 million as of December 31, 2023. Additionally, Insighta2, our 50/50 joint venture in early cancer detection with Professor Dennis Lo, had a cash balance of US$79.1 millio
Show less
Read more
Impact Snapshot
Event Time:
PRE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PRE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PRE alerts
High impacting Prenetics Global Limited - Class A Ordinary Share news events
Weekly update
A roundup of the hottest topics
PRE
News
- Immutep, Capricor Therapeutics, Cyclacel Pharmaceuticals among healthcare movers [Seeking Alpha]Seeking Alpha
- Prenetics Global Limited (NASDAQ: PRE) had its price target lowered by analysts at Cantor Fitzgerald from $10.00 to $9.00. They now have an "overweight" rating on the stock.MarketBeat
- Prenetics Announces Fourth Quarter and Full Year 2023 Financial Results [Yahoo! Finance]Yahoo! Finance
- Prenetics Announces Fourth Quarter and Full Year 2023 Financial Results [Yahoo! Finance]Yahoo! Finance
- Prenetics Announces Fourth Quarter and Full Year 2023 Financial ResultsPR Newswire
PRE
Analyst Actions
- 4/4/24 - Cantor Fitzgerald
PRE
Sec Filings
- 5/1/24 - Form 20-F
- 5/1/24 - Form S-8
- 4/1/24 - Form 6-K
- PRE's page on the SEC website